Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.48, $0.21 better than the analyst estimate of $0.27. Revenue for the quarter came in at $115.9 million versus the consensus estimate of $105.47 million.

Guidance:

• Net product sales in the range of $435 million to $455 million. Guidance reflects the Company’s expectation that wholesaler and pharmacy channel inventory levels will revert to historical 2018 levels, thereby affecting 2019 net product sales by approximately $10 million.
• Research and development expenses in the range of $70 million to $80 million.
• Operating earnings in the range of $160 million to $180 million.
• Effective tax rate of approximately 23% to 25%.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.